Showing results (131-140 of 266) with videos related to

Sort By:
Pageof 27
Pharmacogenomics|August 18, 2010
CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancerRalf Metzger, Lukas Heukamp, Uta Drebber, et al.
International Journal of Cancer|July 3, 2026
MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate TherapyTillmann Bedau, Thomas Zander, Hans Anton Schlößer, et al.
Oncology Reports|December 22, 2007
Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMFUdo Siebolts, Jürgen Thiele, Thomas Zander, et al.
Journal of Cancer Research and Clinical Oncology|April 28, 2022
Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinomaAlexander Damanakis, Patrick Sven Plum, Florian Gebauer, et al.
Journal of Neurology|August 27, 2002
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendrogliomaThomas Zander, Willy Nettekoven, Jürgen A Kraus, et al.
Molecular and Clinical Oncology|May 23, 2017
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug targetHeike Loeser, Dirk Waldschmidt, Fabian Kuetting, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2012
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PETMatthias Scheffler, Carsten Kobe, Thomas Zander, et al.
British Journal of Cancer|July 8, 2026
Proteomic characterization of SMARCA-deficient esophageal adenocarcinoma reveals complement evasion and DNA repair-associated prognostic subgroupsBastian Grothey, Max Krämer, Matteo Montalbano, et al.
International Journal of Cancer|March 5, 2026
Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro-inflammatory tumor microenvironment in esophageal adenocarcinomaBastian Grothey, Heike Löser, Tillmann Bedau, et al.
The AAPS Journal|August 20, 2015
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer PatientsAhmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, et al.
Pageof 27